Author

K. A. Gallo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

R. R. Neubig· 3 shared S. A. Misek· 3 shared A. I. Doseff· 1 shared A. McAuliff· 1 shared B. C. Matson· 1 shared B. Chen· 1 shared B. M. Foda· 1 shared D. P. Hollern· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. R. Neubig

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade

B. M. Foda, S. A. Misek, K. A. Gallo, R. R. Neubig

This study shows that inhibiting the Rho/MRTF pathway with CCG-257081 enhances the effectiveness of PD1/PDL1 blockade in BRAF-resistant melanoma.

bioRxiv · Dec 20, 2023Cancer Biology

BRAF inhibitor resistance confers increased sensitivity to mitotic inhibitors

S. Misek, T. Dexheimer, M. Akram, S. E. Conrad, J. C. Schmidt, R. R. Neubig, K. A. Gallo

This study identifies that BRAF inhibitor-resistant melanoma cells are more sensitive to mitotic inhibitors, revealing a potential therapeutic strategy for resistant tumors.

bioRxiv · Apr 15, 2021Cancer Biology

Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells

S. A. Misek, P. A. Newbury, E. Chekalin, S. Paithankar, A. I. Doseff, B. Chen, K. A. Gallo, R. R. Neubig

This study identifies ibrutinib as a drug that reverses BRAFi resistance in melanoma by inhibiting YAP1 and acting through SRC kinase off-target effects, not BTK.

bioRxiv · Mar 25, 2020Cancer Biology

E2F1 Drives Breast Cancer Metastasis by Regulating the Target Gene FGF13 and Altering Cell Migration

D. P. Hollern, M. R. Swiatnicki, J. P. Rennhack, S. A. Misek, B. C. Matson, A. McAuliff, K. A. Gallo, K. M. Caron, E. R. Andrechek

This study identifies E2F1 as a master regulator of metastasis by upregulating Fgf13, which promotes breast cancer cell migration and pulmonary metastasis.

bioRxiv · Jun 13, 2019Cancer Biology